IDEAYA Biosciences (NASDAQ:IDYA) Director Timothy M. Shannon acquired 400,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was acquired at an average price of $10.00 per share, for a total transaction of $4,000,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NASDAQ:IDYA opened at $6.60 on Thursday. The stock’s fifty day moving average price is $7.38. IDEAYA Biosciences has a 52 week low of $6.12 and a 52 week high of $16.90.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Monday, August 12th. The company reported ($1.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.66). Sell-side analysts predict that IDEAYA Biosciences will post -3.02 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in IDYA. Cubist Systematic Strategies LLC acquired a new position in IDEAYA Biosciences during the second quarter worth $49,000. BlackRock Inc. acquired a new position in IDEAYA Biosciences during the second quarter worth $82,000. Laurion Capital Management LP acquired a new position in IDEAYA Biosciences during the second quarter worth $199,000. Vanguard Group Inc. acquired a new position in IDEAYA Biosciences during the second quarter worth $349,000. Finally, Monashee Investment Management LLC acquired a new position in IDEAYA Biosciences during the second quarter worth $354,000. Institutional investors own 0.62% of the company’s stock.

IDYA has been the topic of a number of recent analyst reports. Citigroup initiated coverage on IDEAYA Biosciences in a report on Monday, June 17th. They issued a “buy” rating and a $20.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on IDEAYA Biosciences in a report on Monday, June 17th. They issued a “neutral” rating and a $15.00 price objective on the stock. Finally, Jefferies Financial Group assumed coverage on IDEAYA Biosciences in a research note on Monday, June 17th. They set a “buy” rating and a $14.00 price target on the stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

See Also: Google Finance Portfolio Tips and Tricks

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.